Amyotrophic Lateral Sclerosis – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Amyotrophic Lateral Sclerosis – Pipeline Review, H2 2019’, provides an overview of the Amyotrophic Lateral Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis

– The report reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Amyotrophic Lateral Sclerosis therapeutics and enlists all their major and minor projects

– The report assesses Amyotrophic Lateral Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Amyotrophic Lateral Sclerosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“1st Bio Therapeutics Inc

AB Science SA

Above and Beyond Concierge Therapeutics LLC

AC Immune SA

Acceleron Pharma Inc

Aclipse One Inc

AcuraStem Inc

Affichem SA

AL-S Pharma AG

Alexion Pharmaceuticals Inc

Alsonex Pty Ltd

Amylyx Pharmaceutical Corp

Anavex Life Sciences Corp

Anelixis Therapeutics LLC

Anida Pharma Inc

Ankar Pharma SL

Annexon Inc

Apic Bio Inc

Apogenix AG

ApoPharma Inc

Aquinnah Pharmaceuticals Inc

ArmaGen Inc

ArunA Biomedical Inc

Athira Pharma Inc

Autophagy Neurotherapeutics Inc

Avanir Pharmaceuticals Inc

AveXis Inc

Axovant Gene Therapies Ltd

AZTherapies Inc

Bach Pharma Inc

Bausch Health Companies Inc

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

BioHealthonomics Inc

Bioinova sro

BrainStorm Cell Therapeutics Inc

Bruschettini Srl

Calico LLC

CavoGene LifeSciences

CellCure

Cerion LLC

Chaperone Therapeutics Inc

Chemigen LLC

CholesteniX Ltd

Chronos Therapeutics Ltd

Chugai Pharmaceutical Co Ltd

Clene Nanomedicine Inc

Cogentis Therapeutics Inc

Collaborative Medicinal Development LLC

Constant Therapeutics LLC

Corcept Therapeutics Inc

Corestem Inc

CSPC NBP Pharmaceutical Co Ltd

Curatis AG

CuroNZ Ltd

Cytokinetics Inc

Daiichi Sankyo Co Ltd

Denali Therapeutics Inc

Disarm Therapeutics Inc

Eikonizo Therapeutics Inc

Eisai Co Ltd

Elysium Health Inc

Emerald Health Sciences Inc

EnhanX Biopharm Inc

Epigen Biosciences Inc

Everfront Biotech Inc

Gemac SA

Gene Therapy Research Institution Co Ltd

Genentech Inc

Genervon Biopharmaceuticals LLC

GeNeuro SA

Genuv Inc

Gilead Sciences Inc

Glialogix Inc

GlyTag LLC

GNT Pharma Co Ltd

Grifols SA

Guangzhou Magpie Pharmaceutical Co Ltd

Helixmith Co Ltd

Hemostemix Inc

Herantis Pharma Plc

Immunity Pharma Ltd

Implicit Bioscience Ltd

ImStar Therapeutics Inc

Ionis Pharmaceuticals Inc

Iron Horse TherapeuticsInc

J2H Biotech

Junaxo Inc

K Pharma Inc

K-Pax Pharmaceuticals Inc

K-Stemcell Co Ltd

Kadimastem Ltd

Keapstone Therapeutics Ltd

KineMed Inc

Klogene Therapeutics Inc

Kringle Pharma Inc

Kyorin Pharmaceutical Co Ltd

Kyowa Kirin Co Ltd

Lascco SA

Lauren Sciences LLC

LifeSplice Pharma LLC

Locana Inc

Maas Biolab

MedDay SA

MeiraGTx Holdings Plc

Meta-IQ ApS

MetVital Inc

MimeTech Srl

Miragen Therapeutics Inc

Mitoconix Bio Ltd

MitoDys Therapeutics Ltd

Mitsubishi Tanabe Pharma Corp

Nanna Therapeutics Ltd

NeuExcell Therapeutics Inc

Neuracle Science Co Ltd

Neurimmune Holding AG

Neurodegeneration Therapeutics Inc

Neurodyn Life Sciences Inc

Neuropore Therapies Inc

NeuroSense Therapeutics Ltd

Neurotune AG

New Biotic Inc

Novartis AG

NuNerve Pty Ltd

OptiKira LLC

Orbis Biosciences Inc

Orion Corp

Orphazyme A/S

Orpheris Inc

Oxford BioMedica Plc

Pfizer Inc

Pharnext SA

Plex Pharmaceuticals Inc

Priavoid GmbH

Prilenia Therapeutics Development Ltd

ProMIS Neurosciences Inc

Prothena Corp Plc

Prous Institute for Biomedical Research SA

PTC Therapeutics Inc

Q Therapeutics Inc

QurAlis Corp

Ra Pharmaceuticals Inc

RASRx LLC

Relmada Therapeutics Inc

reMYND NV

Retrotope Inc

Revalesio Corp

Sangamo Therapeutics Inc

Seneca Biopharma Inc

Shinkei Therapeutics LLC

Spedding Research Solutions SAS

Stealth BioTherapeutics Corp

Talon Pharmaceutical Services Inc

Thera Neuropharma Inc

Theratome Bio Inc

TikoMed AB

Tiziana Life Sciences Plc

Tolerion Inc

Tranquis Therapeutics Inc

Treeway BV

Trucode Gene Repair Inc

Ultragenyx Pharmaceutical Inc

UniQure NV

Verge Genomics Inc

Voyager Therapeutics Inc

Wave Life Sciences Ltd

Xalud Therapeutics Inc

Xcelthera INC

Xonovo Inc

Yooyoung Pharm Co Ltd

Yumanity Therapeutics

ZZ Biotech LLC”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Amyotrophic Lateral Sclerosis Overview 8

Amyotrophic Lateral Sclerosis Therapeutics Development 9

Amyotrophic Lateral Sclerosis Therapeutics Assessment 33

Amyotrophic Lateral Sclerosis Companies Involved in Therapeutics Development 49

Amyotrophic Lateral Sclerosis Drug Profiles 90

Amyotrophic Lateral Sclerosis Dormant Projects 506

Amyotrophic Lateral Sclerosis Discontinued Products 516

Amyotrophic Lateral Sclerosis Product Development Milestones 518

Appendix 529

List of Tables

“List of Tables

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Products under Development by Companies, H2 2019 (Contd..10), H2 2019

Products under Development by Companies, H2 2019 (Contd..11), H2 2019

Products under Development by Universities/Institutes, H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..5), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..5), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Amyotrophic Lateral Sclerosis – Pipeline by 1st Bio Therapeutics Inc, H2 2019

Amyotrophic Lateral Sclerosis – Pipeline by AB Science SA, H2 2019

Amyotrophic Lateral Sclerosis – Pipeline by Above and Beyond Concierge Therapeutics LLC, H2 2019

Amyotrophic Lateral Sclerosis – Pipeline by AC Immune SA, H2 2019

Amyotrophic Lateral Sclerosis – Pipeline by Acceleron Pharma Inc, H2 2019

Amyotrophic Lateral Sclerosis – Pipeline by Aclipse One Inc, H2 2019

Amyotrophic Lateral Sclerosis – Pipeline by AcuraStem Inc, H2 2019

Amyotrophic Lateral Sclerosis – Pipeline by Affichem SA, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports